Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial-Reference-Cited by-同舟云学术

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

Published:2019-06 Issue:6 Volume:30 Page:945-952
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hrebien S.,Citi V.,Garcia-Murillas I.,Cutts R.,Fenwick K.,Kozarewa I.,McEwen R.,Ratnayake J.,Maudsley R.,Carr T.H.,de Bruin E.C.,Schiavon G.,Oliveira M.,Turner N.

Funder

AstraZeneca

Boehringe-Ingelheim

Cascadian Therapeutics

Celldex

Genentech

GlaxoSmithKline

Immunomedics

Novartis

Seattle Genetics

Philips Healthcare

Piqur

PUMA Biotechnology

Roche

Sanofi

GSK

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz085/28492174/mdz085.pdf

Reference28 articles.

1. Analysis of circulating tumor DNA to monitor metastatic breast cancer;Dawson;N Engl J Med,2013

2. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA;Murtaza;Nature,2013

3. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA;Forshew;Sci Transl Med,2012

4. Detection of circulating tumor DNA in early- and late-stage human malignancies;Bettegowda;Sci Transl Med,2014

5. Circulating mutant DNA to assess tumor dynamics;Diehl;Nat Med,2008

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving value assessment of cancer therapies: Results from a modified Delphi study;Health Policy OPEN;2024-12

2. An electrochemical biosensor based on mild reduction-activated CRISPR/Cas12a system for sensitive detection of circulating tumor cells;Biosensors and Bioelectronics;2024-10

3. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence;Scientific Reports;2024-08-31

4. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

5. Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer;International Journal of Cancer;2024-08-11